Cooperative Agreement U01CA298763
Award Date
7/3/25
Completion Date
6/30/29
Dollars Obligated
$481K
Federal Agency
National Cancer Institute
Federal Grant Program
93.395
Assistance Type
Cooperative Agreement
Place of Performance
Ohio, USA
Similar Awards
This Project Grant award from the National Cancer Institute (NCI), under the federal Cancer Research Manpower program (CFDA 93.398), provides $290,017 to St. Jude Children's Research Hospital Inc. to investigate the maintenance of cell state hierarchy within fusion-negative rhabdomyosarcoma (FN-RMS), a pediatric soft tissue cancer. The key objectives are to: 1) use computational and experimental biology tools to study the transcriptional and epigenetic determinants of FN-RMS progenitor-like cell...
This $4,653,104 Cooperative Agreement award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research to discover and develop small molecule agents that can modulate the PAX3-FOXO1 fusion oncoprotein driving the highly fatal fusion-positive alveolar rhabdomyosarcoma (FP-RMS) cancer. The project involves a multi-institutional team with expertise in high-throughput screening, chemoproteomics, molecular biology, medicinal chemistry, and pharmacology. Key goals...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $194,013 to Sanford Research, a non-profit biomedical research organization, to develop the first genetically engineered mouse models that accurately replicate key features of human high-risk rhabdomyosarcoma. The goal is to use these advanced preclinical models to explore the role of the NOTCH1 signaling pathway as both a driver and potential therapeutic target for this aggressive form...
The federal Project Grant award of $624,000.00, provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program, supports advanced biomedical research aimed at transforming healthcare for military service members, veterans, and the broader public. The award, with a performance period from September 1, 2025, to August 31, 2027, will fund a comprehensive in vivo phenotyping study of fusion-driven pediatric rhabdomyosarcomas conducted by the...
This Cooperative Agreement award from the National Cancer Institute (NCI), under the federal Cancer Cause and Prevention Research (CFDA 93.393) program, provides $601,250 in funding to St. Jude Children's Research Hospital to study the underlying mechanisms of ependymoma, an aggressive pediatric brain tumor. The key objectives are to: (1) understand how the ZFTA-RELA fusion oncoprotein forms chromatin-associated condensates to regulate oncogenic gene expression and tumor development, (2)...
This Cooperative Agreement award from the Food and Drug Administration (FDA) under the FDA Research program (CFDA 93.103) provides $1,496,492.00 to the Sloan-Kettering Institute for Cancer Research to conduct research on elucidating tumor-specific cell surface proteomes in ultra-rare cancers like rhabdoid tumors and desmoplastic small round cell tumors. The goal is to gain a better understanding of these challenging, therapy-resistant cancers and identify potential new therapeutic targets. The...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $131,300 to Middle Tennessee State University to develop a novel dual inhibitor for the treatment of MYCN-amplified neuroblastoma. The key objectives are to: Identify the genes regulated by the N-MYC oncogene and its cofactors WDR5 and G9A, and determine how combined inhibition of these cofactors impacts N-MYC-dependent transcription. Pursue the identification and screening of potential...
This Project Grant award of $452,549, funded by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research), supports research at Emory University and its sub-awardee Baylor College of Medicine to comprehensively characterize and genetically perturb the molecular features of MYC-amplified osteosarcoma (OS), a high-risk subgroup with poor prognosis. The research aims to define the intrinsic and extrinsic tumor microenvironment dynamics driven by the MYC oncogene, and develop novel...
The National Cancer Institute (NCI) awarded a Project Grant (CFDA 93.393 - Cancer Cause and Prevention Research) worth $718,113 to St. Jude Children's Research Hospital Inc. on January 15, 2025. The grant supports research aimed at understanding the mechanisms by which the MYC oncogenes interact with core regulatory circuitry transcription factors (CRC TFs) and epigenetic modifiers, such as histone deacetylases (HDAC) and histone lysine demethylase 4 family (KDM4), to promote neuroblastoma...
This federal Project Grant award of $267,298 from the National Cancer Institute (NCI) under CFDA 93.395 - Cancer Treatment Research supports research aimed at targeting the CDK4/6 pathway in translocation renal cell carcinoma (TRCC), an aggressive and difficult-to-treat form of kidney cancer. The primary goals of this 2-year award, which runs from February 2025 to January 2027, are to evaluate the sensitivity of TRCC cells to CDK4/6 inhibition, both alone and in combination with PI3K/mTOR...